综述

M蛋白干扰临床实验室检测项目的研究进展

展开
  • 1.江苏省苏州市苏州大学附属太仓市第一人民医院检验科,江苏 太仓 215400
    2.上海交通大学医学院附属瑞金医院 a.风湿免疫科,b.检验科,上海 200025

收稿日期: 2023-06-25

  网络出版日期: 2023-12-18

基金资助

国家自然科学基金(82271820);国家自然科学基金(82371799)

Advancements in M protein interference in the clinical laboratory detection

Expand
  • 1. Department of Medical Laboratory Center, The First People's Hospital of Taicang, Taicang Affiliated Hospital of Soochow University, Taicang 215400
    2a. Department of Rheumatology and Immunology, 2b. Department of Laboratory Medicine, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200025

Received date: 2023-06-25

  Online published: 2023-12-18

摘要

M蛋白是一种特殊的免疫球蛋白,其存在可能影响一些临床血液检验项目的实验室检测结果。M蛋白的干扰存在于检验前、检验中和检验后,严重影响其他检测项目的准确性。在血清肌酐、尿酸、脂蛋白、总蛋白、胆红素、血糖、血磷、血红蛋白、糖化白蛋白检测中,高浓度的M蛋白可造成结果出现假性高值或假性低值;在25-OH维生素D、促甲状腺素、C反应蛋白、万古霉素、庆大霉素、丙戊酸钠药物浓度的检测中,M蛋白的异常存在干扰了实际检测结果。针对以上问题,解决方案包括如检验前稀释血清或去除蛋白、检验中使用蛋白稳定剂或优化反应条件等。临床上,还可以发现隐匿性的M蛋白,能够在疾病发生前有效检出M蛋白,对于疾病的治疗和预后发展都将出现新的转机。

关键词: M蛋白; 干扰; 实验室检测

本文引用格式

潘晓园, 石慧, 曹季军, 施新明, 史册 . M蛋白干扰临床实验室检测项目的研究进展[J]. 诊断学理论与实践, 2023 , 22(04) : 407 -411 . DOI: 10.16150/j.1671-2870.2023.04.013

Abstract

M protein is a unique immunoglobulin type that often affects the laboratory results of certain blood tests. The M protein interference exits in the pre-analytical, analytical and post-analytical process, seriously affecting the accuracy of tests. For example, high concentrations of M protein in serum creatinine, uric acid, lipoprotein, total protein, bilirubin, blood glucose, phosphorus, hemoglobin, glycosylated albumin can cause false high or false low results. The abnormal presence of M protein in 25-OH vitamin D, thyroid-stimulating hormone, c-reactive protein, vancomycin, gentamicin and sodium valproate concentrations interferes with the actual detection results. Solutions to the above problems include diluting serum or removing protein before testing, using protein stabilizers during testing or optimizing reaction conditions. Furthermore, in clinical practice, hidden M protein can be uncovered, and effective detection prior to the onset of disease can open new avenues for disease management and prognosis.

参考文献

[1] COWAN A J, GREEN D J, KWOK M, et al. Diagnosis and management of multiple myeloma: a review[J]. JAMA, 2022, 327(5):464-477.
[2] LANDGREN O. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events[J]. Hematology Am Soc Hematol Educ Program, 2021, 2021(1):662-672.
[3] MASE H, HAMANO N, MIZUHARA R, et al. Falsely Elevated Serum Creatinine Associated With IgM Paraproteinemia[J]. Kidney Int Rep, 2019, 5(3):377-381.
[4] SHIMAMURA Y, MAEDA T, OGAWA Y, et al. Unusual manifestation of monoclonal gammopathy of undetermined significance: a false serum creatinine elevation[J]. CEN Case Rep, 2020, 9(2):109-113.
[5] NAUTI A, BARASSI A, MERLINI G, et al. Paraprotein interference in an assay of conjugated bilirubin[J]. Clin Chem, 2005, 51(6):1076-1077.
[6] LANGMAN L J, ALLEN L C, ROMASCHIN A D. Interference of IgM paraproteins in the Olympus AU800 uric acid assay[J]. Clin Biochem, 1998, 31(7):517-521.
[7] YILMAZ N S, SEN B, GULBAHAR O. Contribution of the laboratory to a diagnosis process by sequential reflective testing: Paraprotein interference on a direct bilirubin assay[J]. Biochem Med (Zagreb), 2021, 31(2):020801.
[8] SONG L, TONG K H, CHIN C D. Gelation of monoclonal protein was the cause of interference with a total bilirubin assay[J]. J Appl Lab Med, 2019, 3(6):1054-1058.
[9] MELVILLE A, THOMAS S D C. Paraprotein interference of automated total bilirubin measurement[J]. Pathology, 2022, 54(3):365-367.
[10] TSAI L Y, TSAI S M, LEE S C, et al. Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein[J]. Clin Chim Acta, 2005, 358(1-2):192-195.
[11] MONK C, WALLAGE M, WASSELL J, et al. A monoclonal protein identified by an anomalous lipaemia index[J]. Ann Clin Biochem, 2009, 46(Pt 3):250-252.
[12] TICHY M, FRIEDECKY B, BUDINA M, et al. Interfe-rence of IgM-lambda paraprotein with biuret-type assay for total serum protein quantification[J]. Clin Chem Lab Med, 2009, 47(2):235-236.
[13] KRITMETAPAK K, DUMRONGSUKIT S, JINCHAI J, et al. Pseudohyperphosphatemia in a patient with relapsed multiple myeloma after bone marrow transplantation: a case report[J]. Clin Case Rep, 2019, 7(7):1426-1429.
[14] KIKI I, GUNDOGDU M, KAYA H. Spuriously high phosphate level which is promptly resolved after plasmaphe-resis in a patient with multiple myeloma[J]. Transfus Apher Sci, 2007, 37(2):157-159.
[15] BOSSARD V, SAUVAGEON Y, FRAISSINET F, et al. False paraprotein-induced hypoglycemia in the measurement of glucose by the hexokinase method[J]. Ann Biol Clin (Paris), 2019, 77(4):439-445.
[16] KURAMOTO N, WAKAHARA T, TAMAGAWA Y, et al. A case of monoclonal gammopathy of undetermined significance with abnormal low levels of plasma glycated albumin by M protein[J]. Clin Chim Acta, 2018, 487:337-340.
[17] ROBERTS W L, FONTENOT J D, LEHMAN C M. Overe-stimation of hemoglobin in a patient with an IgA-kappa monoclonal gammopathy[J]. Arch Pathol Lab Med, 2000, 124(4):616-618.
[18] ONG M W, SALOTA R, REEMAN T, et al. Artefactual 25-OH vitamin D concentration in multiple myeloma[J]. Ann Clin Biochem, 2017, 54(6):716-720.
[19] HAGER H B, BOLSTAD N, WARREN D J, et al. Falsely markedly elevated 25-hydroxyvitamin D in patients with monoclonal gammopathies[J]. Clin Chem Lab Med, 2020, 59(4):663-669.
[20] LUZZI V I, SCOTT M G, GRONOWSKI A M. Negative thyrotropin assay interference associated with an IgGkappa paraprotein[J]. Clin Chem, 2003, 49(4):709-710.
[21] YU A, PIRA U. False increase in serum C-reactive protein caused by monoclonal IgM-lambda: a case report[J]. Clin Chem Lab Med, 2001, 39(10):983-987.
[22] LEGATT D F, BLAKNEY G B, HIGGINS T N, et al. The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals[J]. Ther Drug Monit, 2012, 34(3):306-311.
[23] DIMESKI G, BASSETT K, BROWN N. Paraprotein interference with turbidimetric gentamicin assay[J]. Biochem Med (Zagreb), 2015, 25(1):117-124.
[24] FORNI G L, PINTO V, MUSSO M, et al. Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgG[J]. Am J Hematol, 2013, 88(12):1045-1049.
[25] KHANT M, FLORKOWSKI C, LIVESEY J, et al. Insulin autoimmune syndrome due to IgG kappa paraprotein[J]. Pathology, 2004, 36(1):86-87.
[26] WU X Y, YIN Y F, TENG J L, et al. IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report[J]. BMC Immunol, 2017, 18(1):32.
[27] VON LANDENBERG P, SCH?LMERICH J, ANDREESEN R, et al. A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody[J]. Rheumatol Int, 2002, 22(3):129-131.
[28] DJUNIC I, ELEZOVIC I, ILIC V, et al. The effect of paraprotein on platelet aggregation[J]. J Clin Lab Anal, 2014, 28(2):141-146.
[29] DJUNIC I, ELEZOVIC I, VUCIC M, et al. Specific bin-ding of paraprotein to platelet receptors as a cause of platelet dysfunction in monoclonal gammopathies[J]. Acta Haematol, 2013, 130(2):101-107.
[30] RANI P, KUMAR T, KUMAR S, et al. IgA monoclonal gammopathy with pseudohyperphosphatemia[J]. Indian J Clin Biochem, 2022, 37(1):119-123.
文章导航

/